Kangfang bioCD47 monoantial initiated clinical

AK117 from insight database () is a new anti-CD47 monoclonal antibody developed by Kangfang Bio.
CD47 is a widely expressed cross-membrane glycoprotein, also known as a whole protein-related protein (IAP), which is highly expressed in a variety of tumor cells and binds to the N end of the macrophage surface signal-regulating protein α (SIRP alpha) to inhibit the phagocytosis.
cd47 drug monodrology and combined therapy have shown good anti-tumor efficacy in both blood tumors and solid tumors, and are the hot targets of the next generation of tumor immunotherapy.
, however, due to the widespread expression of CD47 on the surface of red blood cells, targeted CD47 drugs can lead to devouration and coagulation of red blood cells, affecting the safety and tolerance of their use.
AK117, through its unique structure, retains anti-tumor activity while eliminating red blood cell coagulation and significantly reducing its mediated macrophage-to-red blood cell phagocytosphagy activity, promising to become a better clinically served anti-CD47 drug.
, a clinical trial of AK117 abroad has also been launched and the first patient drug deliveries were completed in Australia in May this year, according to Kangfang BioShare.
, there is no CD47 single resistance approved for listing worldwide.
, however, according to Insight database statistics, the world has 24 enterprises layout of the target products, not only CD47 monoantibodies, but also for CD47 and other targets of dual-specific antibodies, including 10 domestic enterprises.
Source: Insight Database () CD47 is considered highly promising by the industry, and in March, Gilead's $4.9 billion acquisition of Forty Seven, a CD47-focused inhibitor, was another big acquisition by Gilead following its $1.2 billion acquisition of CAR-T therapeutics developer Kite Pharma in 2017.
as recently as September 4 this year, Tiantian Bio reached a nearly $3 billion partnership with AbbVie on the global development and commercialization of the former's self-developed CD47 single-resistant TJC4

AbbVie will be granted the right to develop and commercialize lemzoparlimab in countries and regions outside Greater China, and Tiantian Life reserves all rights to the development and commercialization of lemzoparlimab in Chinese mainland, Hong Kong, China, and Macau, China.
these two high-priced cooperation to bring the CD47 target back to life, but also to the global market to reveal important information, CD47 this target has great potential.
believe that as more clinical trials advance, CD47, a target drug candidate, will bring more good news.
。